Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCase Comprehensive Cancer Center
About this trial
The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.
Eligibility criteria
Qualifiers
All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
Subject must meet program eligibility criteria* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
HLA-identical related donor or unrelated human donor source with bone marrow graft.
Subjects must provide a written informed consent.
Disqualifiers
History of allergy or intolerance to NR precursor compounds, including niacin or nicotinamide
Pregnant or breastfeeding women are excluded from this study since allogeneic HCT is a strict contraindication.
Subjects with uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
Trial design
Treatments tested in this trial
- Nicotinamide riboside (NR)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov